Product Description
Novel peptide HTPEP-001 which blocks TGF-beta signaling in both cellular and fibrosis animal models. (Sourced from: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e15200)
Mechanisms of Action: TSP1 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chengdu Huitai Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for HTPEP-001](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lung Diseases, Interstitial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20241874 | P1 |
Unknown |
Lung Diseases, Interstitial |
None |